Advanced-stage ovarian cancer treated with targeted nanomedicine

Researchers at Rutgers, the State University of New Jersey, have used a targeted nanomedicine approach to deliver small molecule drugs and successfully treat mice with deadly advanced-stage ovarian cancer.Writing about their work in a recent print issue of the journal Clinical Cancer Research, the team explains how an out-of-control protein called CD44 aids tumor growth and development of drug resistance in advanced-stage ovarian cancer.Ovarian cancer is the deadliest gynecological cancer in the United States.

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/kNwW_FQDc_U/269923.php

sport sport medical sport news